Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.
Atezolizumab
Cost-effectiveness analysis
IMpower110 trial
Non-small cell lung cancer
PD-L1 expression
Pembrolizumab
Journal
Cost effectiveness and resource allocation : C/E
ISSN: 1478-7547
Titre abrégé: Cost Eff Resour Alloc
Pays: England
ID NLM: 101170476
Informations de publication
Date de publication:
16 Jan 2023
16 Jan 2023
Historique:
received:
04
08
2022
accepted:
08
01
2023
entrez:
16
1
2023
pubmed:
17
1
2023
medline:
17
1
2023
Statut:
epublish
Résumé
Atezolizumab has recently been approved for first-line treatment of high PD-L1 expression metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR or ALK mutations, on the basis of the IMpower110 trial. This study aims to estimate the cost-effectiveness of atezolizumab compared with pembrolizumab among these patients in Spanish settings, based on the results of the two cut-offs of the IMpower110 study. A three-state partitioned-survival model was adapted to Spanish settings to calculate health outcomes and costs over a lifetime horizon. Clinical data for atezolizumab were collected from the interim and the exploratory results (data cut-off: Sept'18 and Feb'20, respectively) of the IMpower110 trial while a network meta-analysis was used to model pembrolizumab treatment. Utility data were collected from the trial. Direct medical costs were considered based on resources identified by experts. Costs and outcomes were discounted at 3% per year. Health outcomes were expressed as cost per Life Year (LY) and cost per Quality-Adjusted Life Year (QALY). Both deterministic and probabilistic sensitivity analyses were performed to assess the robustness of results. Over a lifetime horizon, the incremental results showed that atezolizumab generated similar health outcomes (LYs and QALYs) to pembrolizumab, with minimal differences depending on the cut-off used (+ 0.70 and + 0.42 LYs and QALYs with Sept'18 cut-off and - 0.80 and - 0.72 LYs and QALYs with Feb'20 cut-off). However, for both cut-offs, atezolizumab produced meaningfully less costs than pembrolizumab (€ - 54,261 with Sept'18 cut-off and € - 81,907 with Feb'20 cut-off). The sensitivity analyses carried out confirmed the robustness of the base-case results. The cost-effectiveness analysis, comparing the two cut-off of IMpower110, shows that atezolizumab provides similar health gains to pembrolizumab but at a lower cost for the first-line treatment of metastasic NSCLC patients in Spain.
Sections du résumé
BACKGROUND
BACKGROUND
Atezolizumab has recently been approved for first-line treatment of high PD-L1 expression metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR or ALK mutations, on the basis of the IMpower110 trial. This study aims to estimate the cost-effectiveness of atezolizumab compared with pembrolizumab among these patients in Spanish settings, based on the results of the two cut-offs of the IMpower110 study.
METHODS
METHODS
A three-state partitioned-survival model was adapted to Spanish settings to calculate health outcomes and costs over a lifetime horizon. Clinical data for atezolizumab were collected from the interim and the exploratory results (data cut-off: Sept'18 and Feb'20, respectively) of the IMpower110 trial while a network meta-analysis was used to model pembrolizumab treatment. Utility data were collected from the trial. Direct medical costs were considered based on resources identified by experts. Costs and outcomes were discounted at 3% per year. Health outcomes were expressed as cost per Life Year (LY) and cost per Quality-Adjusted Life Year (QALY). Both deterministic and probabilistic sensitivity analyses were performed to assess the robustness of results.
RESULTS
RESULTS
Over a lifetime horizon, the incremental results showed that atezolizumab generated similar health outcomes (LYs and QALYs) to pembrolizumab, with minimal differences depending on the cut-off used (+ 0.70 and + 0.42 LYs and QALYs with Sept'18 cut-off and - 0.80 and - 0.72 LYs and QALYs with Feb'20 cut-off). However, for both cut-offs, atezolizumab produced meaningfully less costs than pembrolizumab (€ - 54,261 with Sept'18 cut-off and € - 81,907 with Feb'20 cut-off). The sensitivity analyses carried out confirmed the robustness of the base-case results.
CONCLUSIONS
CONCLUSIONS
The cost-effectiveness analysis, comparing the two cut-off of IMpower110, shows that atezolizumab provides similar health gains to pembrolizumab but at a lower cost for the first-line treatment of metastasic NSCLC patients in Spain.
Identifiants
pubmed: 36647072
doi: 10.1186/s12962-023-00417-z
pii: 10.1186/s12962-023-00417-z
pmc: PMC9841669
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6Informations de copyright
© 2023. The Author(s).
Références
Clin Transl Oncol. 2019 Jan;21(1):3-17
pubmed: 30446985
Clin Epidemiol. 2011;3:139-48
pubmed: 21607015
J Clin Oncol. 2017 Aug 20;35(24):2781-2789
pubmed: 28609226
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Health Technol Assess. 2010 Jan;14(2):1-184, iii-iv
pubmed: 20028613
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Discov Med. 2019 Mar;27(148):167-170
pubmed: 31095926
Lung Cancer. 2017 Oct;112:200-215
pubmed: 29191596
Br J Cancer. 2003 Sep 15;89(6):1002-7
pubmed: 12966416
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
N Engl J Med. 2017 Aug 31;377(9):849-861
pubmed: 28854088
J Clin Med. 2021 Mar 26;10(7):
pubmed: 33810441
Pharmacoeconomics. 2000 May;17(5):479-500
pubmed: 10977389
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Gac Sanit. 2010 Mar-Apr;24(2):154-70
pubmed: 19959258
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Value Health. 2020 Dec;23(12):1613-1621
pubmed: 33248517
Gac Sanit. 2017 Nov - Dec;31(6):524-530
pubmed: 27707518
Pharmacoeconomics. 2013 Jan;31(1):15-24
pubmed: 23329590
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
Health Technol Assess. 2013 Apr;17(14):1-237
pubmed: 23547747
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Immune Netw. 2017 Dec;17(6):378-391
pubmed: 29302251
Front Oncol. 2021 Jul 09;11:676732
pubmed: 34307144
J Thorac Oncol. 2021 Nov;16(11):1872-1882
pubmed: 34265434